United States:
Sample Shaming : FDA's Open Letter On Access To Samples
06 November 2018
Shearman & Sterling LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Senior associate Timothy Slattery (Washington, D.C.-Antitrust)
has authored the article "Sample Shaming: FDA's Open
Letter on Access to Samples Under REMS Programs Publically Calls
Out Branded Drug Manufacturers to Aid Generic Entry" in
Antitrust Advisors, a publication of the American Health
Lawyers Association Antitrust Practice Group. The article was
published in September 2018.
Read Sample Shaming: FDA's Open Letter on
Access to Samples Under REMS Programs Publically Calls Out Branded
Drug Manufacturers to Aid Generic Entry
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Antitrust/Competition Law from United States
US Antitrust Agencies Release Final Revised Merger Guidelines
Goodwin Procter LLP
On December 18, 2023, the Federal Trade Commission and the Antitrust Division of the Department of Justice released the final version of revised Merger Guidelines, a set of principles Agencies use in their review of mergers and acquisitions.